Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutrition & Santé

This article was originally published in The Tan Sheet

Executive Summary

Novartis has agreed to divest its Nutrition & Santé business to ABN AMRO Capital France for $260 mil. (€1=$1.17) on a cash and debt-free basis, the firm announces Nov. 29. Divestiture is expected to take place in first quarter 2006. Nutrition & Santé comprises the remainder of Novartis' Health & Functional Food business unit; the firm sold a number of assets to Associated British Foods in November 2002 (1"The Tan Sheet" Oct. 14, 2002, In Brief). Nutrition & Santé produces functional foods Gerblé and Céréal, weight loss products Gerlinéa, Pesoforma and Milical and sports nutrition product line Isostar. The firm markets primarily in France, Spain, Portugal, Italy and the Benelux region...

You may also be interested in...

Ovaltine sale overseas

UK-based Associated British Foods picks up rights to malt-based product line worldwide, except for U.S. and Puerto Rico, with acquisition of Novartis' Food & Beverage business for about $267.5 mil. ($1=€1.02), firms announce Oct. 8. Himmel Nutrition has held U.S. licensing rights to Ovaltine since 1992, according to Novartis. Divested F&B business generated approximately $239.5 mil. in 2001 sales, constituting 43% of Health & Functional Food division's revenue; Novartis announced plans to divest the division in February (1"The Tan Sheet" Feb. 11, 2002, p. 12). Negotiations to sell other H&FF businesses, including Sports Nutrition division, "are proceeding," firm says. Benefiber, Resource Wellness supplement lines are housed in Novartis' Medical Nutrition unit, which is not for sale...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts